Search research articles
Contact Us
Filters
Showing results (141-150 of 189) with videos related to
Page
of 19
Sort By:
British Journal of Cancer
|
March 24, 2012
Everolimus in metastatic renal cell carcinoma patients intolerant to previous VEGFr-TKI therapy: a RECORD-1 subgroup analysis
S Bracarda, T E Hutson, C Porta, et al.
Gene Therapy
|
February 26, 2003
Recombinant adenovirus shedding after intratumoral gene transfer in lung cancer patients
F Griscelli, P Opolon, P Saulnier, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie
|
May 25, 2010
[Progress and summary of recent congress: ASCO-GU, EAU, AUA, ASCO about the medical management of locally advanced or metastatic kidney cancer]
J-J Patard, B Escudier, P Paparel, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie
|
December 7, 2010
[Recommendations Onco-Urology 2010: Kidney cancer]
J-J Patard, H Baumert, J-M Corréas, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie
|
March 15, 2011
[Case report of kidney cancer from JOUM 2010]
Y Neuzillet, L Guy, J-A Long, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 1, 1996
Predictors of clinical response to interleukin-2--based immunotherapy in melanoma patients: a French multiinstitutional study
E Tartour, J Y Blay, T Dorval, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 25, 2016
How to report toxicity associated with targeted therapies?
B Cabarrou, J M Boher, E Bogart, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 24, 1999
Cytokines in metastatic renal cell carcinoma: is it useful to switch to interleukin-2 or interferon after failure of a first treatment? Groupe Français d'Immunothérape
B Escudier, C Chevreau, C Lasset, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
May 21, 1999
Combination interleukin-2 and doxorubicin in advanced adult solid tumors: circumvention of doxorubicin resistance in soft-tissue sarcoma?
A Le Cesne, G Vassal, F Farace, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie
|
September 26, 2008
[Kidney cancer management in 2007: news and recommendations]
J-N Cornu, M Rouprêt, H Lang, et al.
Page
of 19
Search research articles
Search
Showing results (141-150 of 189) with videos related to
Sort By:
Page
of 19
British Journal of Cancer
|
March 24, 2012
Everolimus in metastatic renal cell carcinoma patients intolerant to previous VEGFr-TKI therapy: a RECORD-1 subgroup analysis
S Bracarda, T E Hutson, C Porta, et al.
Gene Therapy
|
February 26, 2003
Recombinant adenovirus shedding after intratumoral gene transfer in lung cancer patients
F Griscelli, P Opolon, P Saulnier, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie
|
May 25, 2010
[Progress and summary of recent congress: ASCO-GU, EAU, AUA, ASCO about the medical management of locally advanced or metastatic kidney cancer]
J-J Patard, B Escudier, P Paparel, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie
|
December 7, 2010
[Recommendations Onco-Urology 2010: Kidney cancer]
J-J Patard, H Baumert, J-M Corréas, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie
|
March 15, 2011
[Case report of kidney cancer from JOUM 2010]
Y Neuzillet, L Guy, J-A Long, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 1, 1996
Predictors of clinical response to interleukin-2--based immunotherapy in melanoma patients: a French multiinstitutional study
E Tartour, J Y Blay, T Dorval, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 25, 2016
How to report toxicity associated with targeted therapies?
B Cabarrou, J M Boher, E Bogart, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 24, 1999
Cytokines in metastatic renal cell carcinoma: is it useful to switch to interleukin-2 or interferon after failure of a first treatment? Groupe Français d'Immunothérape
B Escudier, C Chevreau, C Lasset, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
May 21, 1999
Combination interleukin-2 and doxorubicin in advanced adult solid tumors: circumvention of doxorubicin resistance in soft-tissue sarcoma?
A Le Cesne, G Vassal, F Farace, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie
|
September 26, 2008
[Kidney cancer management in 2007: news and recommendations]
J-N Cornu, M Rouprêt, H Lang, et al.
Page
of 19